Quinolines and derivatives
Medchemexpress LLC Sevabertinib (BAY 2927088) | 2521285-05-0 | 99.9% | 484.93 | 200 MG
Sevabertinib (BAY 2927088) is an orally active and reversible dual EGFR-HER2 inhibitor with potent anticancer activity against lung cancer. It shows significantly reduced activity against HER4.
- Orally active and reversible dual EGFR-HER2 inhibitor
- Exhibits anticancer activity against lung cancer
- Potently inhibits proliferation of isogenic Ba/F3 cells ectopically expressing HER2 exon 20 insertions
- Potently inhibits proliferation of isogenic Ba/F3 cells activating HER2 point mutations or putative secondary acquired resistance mutations
- Inhibits proliferation of lung cancer cell lines NCI-H1781 and NCI-H2170
Apexbio Technology LLC CAY10505 1218777-13-9 200mg
CAY10505 is a small-molecule inhibitor targeting phosphatidylinositol 3-kinase gamma (PI3K ) It is designed to selectively inhibit PI3K thereby modulating cellular processes governed by the PI3K/Akt/mTOR signaling pathway CAY10505 exerts its biological activity primarily through inhibition of PI3K In cultured neuron studies CAY10505 demonstrates inhibition of baicalein-induced Akt phosphorylation with an IC50 value of approximately 30 nM Based on these pharmacological properties CAY10505 holds research potential in neuroscience cardiovascular biology and cancer biology studies
Apexbio Technology LLC PF-431396 717906-29-1 200mg
PF-431396 is a pyrimidine-based small-molecule inhibitor targeting proline-rich tyrosine kinase 2 (Pyk2) and focal adhesion kinase (FAK) It is designed to selectively inhibit these kinases thereby modulating signaling pathways involved in cellular adhesion migration and proliferation PF-431396 exerts its biological activity primarily through disruption of Pyk2 and FAK tyrosine autophosphorylation or transphosphorylation Based on these pharmacological properties PF-431396 holds research potential in the investigation of cancer biology inflammation and immunological cell responses in experimental models
Apexbio Technology LLC Ganetespib (STA-9090)(Synonyms: STA-9090, Ganetespib, STA9090, STA 9090), 200mg, CAS: 888216-25-9.
Ganetespib (STA-9090 CAS 888216-25-9) is a small-molecule inhibitor targeting heat shock protein 90 (Hsp90) It binds competitively to the ATP-binding pocket located at the N-terminal region of Hsp90 disrupting its chaperone activity and subsequently causing degradation of client proteins involved in tumor growth and survival Structurally distinct from geldanamycin-derived inhibitors Ganetespib features a triazolone moiety Preclinical studies have demonstrated antitumor activity across various cancer cell types including lung prostate colon breast cancers melanoma and leukemia highlighting its therapeutic potential for cancer research
eMolecules 63875-01-4 | 2-methylpyridine-4-carbaldehyde | Pharmablock | MFCD06410683 | 121.139 | C7H7NO | 97.000 | Cc1cc(C=O)ccn1 | 50mg | 586152837
2-methylpyridine-4-carbaldehyde | Pharmablock | 63875-01-4 | MFCD06410683 | 121.139 | C7H7NO | 97.000 | Cc1cc(C=O)ccn1 | 50mg | 586152837
Apexbio Technology LLC Hexestrol 84-16-2 200mg
Hexestrol (CAS 84-16-2) is a small-molecule agonist targeting estrogen receptors ER and ER It is designed to selectively activate these receptors thereby regulating hormone-responsive gene expression and associated biological pathways Hexestrol exerts its biological activity primarily through direct agonist-mediated activation of ER and ER In in vitro studies Hexestrol demonstrates potent activation with reported EC50 values of approximately 0 07 nM for ER and 0 175 nM for ER Based on these pharmacological properties Hexestrol holds research potential in studies involving estrogen receptor signaling hormone-dependent cellular responses and pathologies related to estrogen deficiency
Medchemexpress LLC Molibresib | 1260907-17-2 | 200 MG
Molibresib (I-BET762; GSK525762) is a BET bromodomain inhibitor with an IC₅₀ of 32.5-42.5 nM. It binds to the tandem bromodomains of BET with high affinity and displaces a tetra-acetylated H4 peptide. It has high affinity for the BD1/BD2 domain of BRD2/3/4 proteins and inhibits OPM-2 cell proliferation.
- BET bromodomain inhibitor
- High affinity for BD1/BD2 domain of BRD2/3/4 proteins
- Inhibits OPM-2 cell proliferation
Apexbio Technology LLC DGAT-1 inhibitor 701232-20-4 200mg
DGAT-1 inhibitor (CAS 701232-20-4) also known as T863 is an orally active small molecule that selectively inhibits diacylglycerol acyltransferase 1 (DGAT1) DGAT1 is responsible for catalyzing the final step in triglyceride biosynthesis T863 suppresses enzyme activity by specifically binding to the acyl-CoA binding site of DGAT1 exhibiting an IC50 of 15 nM without affecting enzymatic activities of human DGAT2 MGAT2 or MGAT3 This compound serves as a research tool for investigating DGAT1-mediated lipid synthesis and exploring lipid metabolic disorders using cellular and animal models
Apexbio Technology LLC GDC-0941 957054-30-7 200mg
GDC-0941 (CAS 957054-30-7) is a selective small-molecule inhibitor of class I phosphoinositide 3-kinase (PI3K) a critical component involved in the PI3K/Akt signaling pathway frequently dysregulated in cancer By competitively binding to the ATP-binding site of PI3K GDC-0941 inhibits generation of the downstream signaling molecule phosphatidylinositol-3 4 5-trisphosphate (PIP3) Exhibiting high selectivity against p110 / (IC50 approx 3 nM) and moderate selectivity for p110 (33 nM) and p110 (75 nM) GDC-0941 has demonstrated antiproliferative activity across diverse tumor cell lines in vitro (e g A2780 PC3 U87MG) and tumor growth inhibition in xenograft cancer models supporting its utility in cancer research
Medchemexpress LLC Emodin | 518-82-1 | 99.3% | C15H10O5 | 200 MG
Emodin (Frangula emodin) is an anthraquinone derivative known for its anti-SARS-CoV properties. It blocks the SARS coronavirus spike protein and angiotensin-converting enzyme 2 (ACE2) interaction. This compound also inhibits casein kinase-2 (CK2) and demonstrates anti-inflammatory and anticancer effects. Furthermore, it is a potent selective 11β-HSD1 inhibitor and has been shown to ameliorate metabolic disorder in diet-induced obese mice.
- Blocks SARS coronavirus spike protein and ACE2 interaction
- Inhibits casein kinase-2 (CK2)
- Exhibits anti-inflammatory effects
- Shows anticancer effects
- Functions as a potent selective 11β-HSD1 inhibitor
- Ameliorates metabolic disorder in diet-induced obese mice
Medchemexpress LLC Rebastinib (DCC-2036) | 1020172-07-9 | 99.84% | 200 MG
Rebastinib is an orally active, non-ATP-competitive inhibitor that targets Bcr-Abl, including its wild-type and T315I mutant forms. It also demonstrates inhibitory activity against SRC, KDR, FLT3, and Tie-2, while showing minimal activity against c-Kit.
- Orally active.
- Non-ATP-competitive inhibition of Bcr-Abl.
- Effective against wild-type and T315I mutant Bcr-Abl.
- Inhibits other kinases such as SRC, KDR, FLT3, and Tie-2.
- Demonstrates low activity toward c-Kit.
- Potently inhibits both inactive and active forms of ABL1.
- Effective against several common TKI-resistant Bcr-Abl mutants.
- Inhibits proliferation of cells expressing Bcr-Abl and Ph+ cell lines.
- Reduces autophosphorylation of Bcr-Abl and phosphorylation of STAT5.
Apexbio Technology LLC Semagacestat (LY450139) 425386-60-3 200mg
Semagacestat (LY450139 CAS 425386-60-3) is a gamma-secretase inhibitor belonging to the azadecalin class investigated for its potential in Alzheimer s disease research By selectively inhibiting gamma-secretase Semagacestat decreases the production rate of beta-amyloid (A ) peptides in both animal models (including mice beagle dogs and guinea pigs) and human subjects A is a principal component of amyloid plaques observed in the brains of Alzheimer s patients In transgenic mouse models expressing mutant human amyloid precursor protein (APP V717F) Semagacestat has been shown to slow A accumulation in the brain and reduce amyloid plaque burden dose-dependently supporting its utility as a tool compound in Alzheimer s disease pathogenesis studies
Medchemexpress LLC Halcinonide | 3093-35-4 | 98.3% | 200 MG
Halcinonide is a high potency corticosteroid used topically in the treatment of certain skin conditions. This product is for research use only and not sold to patients.
- High potency corticosteroid
- Used topically for skin conditions
- For research use only
- Solid appearance
- Light yellow to yellow color
- Molecular weight: 454.96
- Formula: C24H32ClFO5
Apexbio Technology LLC Oxacillin sodium monohydrate 7240-38-2 200mg
Oxacillin sodium monohydrate (CAS 7240-38-2) is a small-molecule inhibitor within the penicillin class It is designed to inhibit bacterial cell wall biosynthesis thereby disrupting peptidoglycan cross-linking and compromising cellular integrity Oxacillin sodium monohydrate exerts its biological activity primarily through interference with peptidoglycan cross-linking resulting in bacterial lysis In in vitro studies Oxacillin sodium monohydrate demonstrates antimicrobial inhibition with minimum inhibitory concentration (IC50) values typically ranging from approximately 0 1 to several g/mL depending on bacterial strain and assay conditions Based on these pharmacological properties Oxacillin sodium monohydrate holds research potential in antimicrobial susceptibility testing resistance phenotyping and investigations of bacterial resistance mechanisms particularly in gram-positive -lactamase-producing bacteria such as methicillin-resistant staphylococci (MRSA)
Medchemexpress LLC Prucalopride succinate | 179474-85-2 | 99.9% | 200 MG
Prucalopride succinate is an orally active, selective, and specific 5-HT4 receptor agonist. It enhances intestinal motility by promoting intestinal nervous system regeneration and exhibits anticancer activity by blocking the PI3K/AKT/mTor pathway. It is used in studies of chronic constipation, pseudo-intestinal obstruction, and cancer.
- Selective and specific 5-HT4 receptor agonist
- Enhances intestinal motility
- Exhibits anticancer activity
- Induces autophagy and apoptosis in A549/A427 cells
- Promotes regeneration of colonic neural stem cells and neurons